Washington – Commercial motor vehicle drivers who fail a drug and alcohol test will be listed on a national clearinghouse to be created by the Federal Motor Carrier Safety Administration, according to a final rule published Dec. 5.
Once established, the clearinghouse will include records of violations of FMCSA’s drug and alcohol testing program. Motor carriers will need to search the system for information related to current and prospective employees who might have unresolved violations that prohibit them from driving. Employers and medical review officers also will be required to report information about drivers who test positive for drugs or alcohol; refuse to comply with drug and alcohol testing; or participate in the return-to-duty drug and alcohol rehabilitation process.
Federal regulations require employers to conduct pre-employment drug testing, in addition to random testing. Employees who test positive are not allowed to perform safety-sensitive functions, which includes driving a CMV.
“An overwhelming majority of the nation’s freight travels by truck, and millions of passengers reach their destinations by bus, so creating a central, comprehensive, and searchable database of commercial motor vehicle drivers who violate the federal drug and alcohol testing requirements has been a departmental priority,” Secretary of Transportation Anthony Foxx said in a Dec. 2 press release. “This system will be a new technological tool that will make our roads safer.”
The final rule is scheduled to go into effect Jan. 4, with a compliance deadline slated for January 2020.
The FDA recently voted in favor of pushing a new formulation of oxycodone hydrochloride for approval. The new OxyContin formula is more difficult to crush or dissolve which will hopefully make it harder to be used as a drug of abuse . The FDA recommended that Purdue Pharma's application for a new, resin-coated formulation should replace the original version, which has been on the market since 1996. Randall Flick, MD, an anesthesiologist at the Mayo Clinic who voted to recommend approval of the drug said, "Clearly the old formulation is worse than the new, although I think the difference is relatively small," Flick concluded, "Hardcore abusers are likely to devise new ways to break down the harder tablet or figure out which solvents will dissolve it fastest, within 'day or weeks' of the product's release on the market."